<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197298</url>
  </required_header>
  <id_info>
    <org_study_id>K14-22</org_study_id>
    <nct_id>NCT03197298</nct_id>
  </id_info>
  <brief_title>Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>CHANGE DAPT</acronym>
  <official_title>Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thorax Centrum Twente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thorax Centrum Twente</source>
  <brief_summary>
    <textblock>
      Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet
      therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides
      aspirin). This change is based on studies that showed benefits of ticagrelor. However, study
      participants were only partly treated by percutaneous coronary intervention (PCI). In
      patients who were treated by PCI, this was generally performed using of bare metal or
      first-generation drug-eluting stents (DES).

      CHANGE DAPT is an investigator-initiated, prospective, single centre registry, in which we
      evaluate the impact of the guideline suggested change in the primary DAPT regimen (from
      clopidogrel to ticagrelor) on 1-year clinical outcome in ACS patients treated by PCI with
      newer-generation DES in the Thoraxcentrum Twente.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2012</start_date>
  <completion_date type="Actual">July 25, 2016</completion_date>
  <primary_completion_date type="Actual">July 25, 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Net adverse clinical and cerebral events (NACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>A composite of all-cause death, any myocardial infarction, stroke, or major bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>According to the Academic Research Consortium (ARC) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>Focal loss of neurologic function caused by an ischemic or hemorrhagic event with residual symptoms lasting at least 24 hours or leading to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>Defined by Thrombolysis in Myocardial Infarction (TIMI) major bleeding or TIMI in the setting of coronary artery bypass grafting, and/or any Bleeding Academic Research Consortium (BARC) class 3 or 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any clinically indicated revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Revascularization by PCI or CABG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>According to the Academic Research Consortium (ARC) definition</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2062</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Drug-Eluting Stents</condition>
  <arm_group>
    <arm_group_label>Clopidogrel Period</arm_group_label>
    <description>ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor Period</arm_group_label>
    <description>ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Clopidogrel Period</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Ticagrelor Period</arm_group_label>
    <other_name>Brilinta</other_name>
    <other_name>Brilique</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the primary cardiac care clinic of the Thoraxcentrum Twente
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presentation with acute coronary syndrome (ACS)

          -  Treated with newer-generation drug-eluting stent (DES) in coronary artery or bypass
             graft lesion

        Exclusion Criteria:

          -  Known pregnancy

          -  Life expectancy less than one year

          -  Planned elective surgery requiring interruption of DAPT in the first 6 months

          -  Known intolerance to components of the DES available

          -  Indication for oral anticoagulation at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clemens von Birgelen, MD,PhD,Prof</last_name>
    <role>Study Director</role>
    <affiliation>Thoraxcentrum Twente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K. Gert van Houwelingen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxcentrum Twente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Drug-Eluting Stents</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>Purinergic P2Y Receptor Antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

